强迫症及相关疾病中的 Epidiolex
2026年7月28日 更新者:University of Chicago
Epidiolex 治疗强迫症及相关疾病的开放标签试验:概念研究证明
拟议研究的主要目的是评估 Epidiolex(大麻二酚)在患有强迫症和相关疾病(OCRD)的成人中的安全性和有效性。
受试者将以开放标签的方式接受 Epidiolex 两周的治疗。
研究概览
详细说明
拟议研究的主要目的是评估 Epidiolex(大麻二酚)在患有强迫症和相关疾病(OCRD)的成人中的安全性和有效性。
OCRD 包括强迫症 (OCD)、拔毛癖、扒皮症、抽动秽语症和囤积症。
这些疾病似乎在现象学和可能的生物学方面都有联系。
十五名患有 OCRD 的受试者将以开放标签的方式接受 Epidiolex(2.5 mg/kg,每天两次,持续一周,然后是 5mg/kg,每天两次),总共两周的积极治疗。
要测试的假设是 Epidiolex 将导致 OCRD 症状的减少(症状的改善将通过先前研究中使用的 OCRD 症状的既定结果测量的较低分数来表示)。
研究类型
介入性
注册 (实际的)
4
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
描述
纳入标准:
- 18-65岁的男性和女性
- 强迫症、囤积症、皮肤挑剔症、拔毛癖或抽动秽语综合症的初步诊断
- 基线时 YBOCS 分数至少为 18
- 理解和签署同意书的能力。
排除标准:
- 基于病史的不稳定内科疾病或基线体检或实验室的临床显着异常
- 目前怀孕或哺乳,或育龄妇女避孕措施不充分
- 根据哥伦比亚自杀严重程度评定量表 (C-SSRS),受试者被认为有直接自杀风险
- 过去 12 个月的 DSM-5 精神障碍而非强迫症
- 基于尿液毒理学筛查的非法物质使用
- 筛选后 3 个月内开始心理干预
- 使用任何其他精神药物
- 以前用 Epidiolex 治疗过
- 干扰理解和自我管理药物或提供书面知情同意的能力的认知障碍
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Epidiolex
Epidiolex(2.5 mg/kg,每天两次,持续一周),然后是 Epidiolex(5mg/kg,每天两次,持续两周)
|
Epidiolex 口服溶液(2.5 mg/kg 和 5 mg/kg)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Yale Brown Obsessive Compulsive Scale (YBOCS) Total Score
大体时间:Baseline to Week 2
|
The primary outcome measure will be the change from baseline using the Yale Brown Obsessive Compulsive Scale (YBOCS).
The YBOCS is a 10-item scale that assesses OCD symptoms during the last seven days.
The first five items comprise the urge/thought subscale and items 6-10 comprise the behavior subscale.
The change in scores from baseline to Week 2 will be reported.
The scores from the subscales are summed together to reach a total score.
The scale ranges from 0-40 with higher scores reflecting more severe symptoms.
|
Baseline to Week 2
|
|
Change in NIMH Symptom Severity Scale (for TTM or Skin Picking) Total Score
大体时间:Baseline to Week 2
|
The primary efficacy measure will be the change in hair pulling or skin picking frequency and urges to pull hair or pick skin for the past week as indicated by change in total score.
The entire study lasts two weeks.
Every two weeks subjects will take the NIMH-TSS.
The change in scores from baseline to Week 2 will be reported.
The scale itself assesses severity of trichotillomania symptoms.
The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe.
|
Baseline to Week 2
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Clinical Global Impressions- Severity Scale (CGI-S) Total Score
大体时间:Baseline to Week 2
|
The entire study for the subject will last 2 weeks.
The subject will complete the CGI once per week.
The change in scores from baseline to Week 2 will be reported.
The scale itself assesses overall disorder severity on a scale from 1 to 7 with 1 being "not at all" and 7 being "among the most severe cases"
|
Baseline to Week 2
|
|
Change in Hamilton Depression Rating Scale (HAM-D) Total Score
大体时间:Baseline to Week 2
|
The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered assessment of depression that will be assessed at all study visits.
The HAM-D is a 17-item scale that assess depressive symptoms during the last seven days.
The change in scores from baseline to Week 2 will be reported.
The scale ranges from 0-52 with higher total scores indicating higher levels of depression, while a score of 0 would indicate no depressive symptoms.
|
Baseline to Week 2
|
|
Change in Hamilton Anxiety Rating Scale (HAM-A) Total Score
大体时间:Baseline to Week 2
|
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment of anxiety that will be assessed at all study visits.
The HAM-A is a 14 item scale that assess anxiety symptoms during the last fourteen days.
The change in scores from baseline to Week 2 will be reported.
The scale ranges from 0-56 with higher scores indicating higher levels of anxiety, with 0 being no symptoms of anxiety.
|
Baseline to Week 2
|
|
Change in Sheehan Disability Scale (SDS) Total Score
大体时间:Baseline to Week 2
|
The Sheehan Disability Scale (SDS) is a self-report scale that subjects will complete the SDS at all visits.
The SDS is a three item scale that measures functional impairment across work/school, social life, and family/home responsibilities during the past seven days.
The change in scores from baseline to Week 2 will be reported.
Each item ranges from 0-10, with higher scores indicating more impairment.
However, only total score is reported which ranges from 0-30, with higher scores indicating more severe impairment.
The total score is computed by summing the three scores from each domain.
The scale itself assesses the level of disability from target disorder with higher scores indicating a more debilitating disorder.
|
Baseline to Week 2
|
|
Change in Quality of Life Inventory (QOLI) Total Score
大体时间:Baseline to Week 2
|
The Quality of Life Inventory (QOLI) is a self-report assessment of patient perceived quality of life that will be assessed at each visit.
The change in scores from baseline to Week 2 will be reported.
The QOLI assesses both the importance and satisfaction of 16 life domains.
Scores are calculated by multiplying the importance score by the satisfaction score which gives a weighted score for each domain.
Each weighted score is then added together to get a total score which ranges from 0-100 with higher scores indicating a higher quality of life, whereas lower scores indicate a lower quality of life.
|
Baseline to Week 2
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Jon E Grant, MD, JD, MPH、University of Chicago
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57.
- HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x. No abstract available.
- Sheehan DV (1983). The Anxiety Disease. New York: Scribner's.
- Frisch MB, Cornell J, Villaneuva M (1993). Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 4:92-101.
- Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995 Aug;56(8):368-73.
- Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by U.S. psychiatrists. J Clin Psychiatry. 2006 Jun;67(6):946-51. doi: 10.4088/jcp.v67n0611.
- Grant JE. Clinical practice: Obsessive-compulsive disorder. N Engl J Med. 2014 Aug 14;371(7):646-53. doi: 10.1056/NEJMcp1402176.
- Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2022年4月14日
初级完成 (实际的)
2025年11月1日
研究完成 (实际的)
2025年11月1日
研究注册日期
首次提交
2021年7月20日
首先提交符合 QC 标准的
2021年7月20日
首次发布 (实际的)
2021年7月27日
研究记录更新
最后更新发布 (实际的)
2026年7月29日
上次提交的符合 QC 标准的更新
2026年7月28日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRB21-1147
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.